A Phase 3 interventional study of Saizen® in Growth Hormone Deficiency (GHD), sponsored by EMD Serono. Terminated at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2013-08-07.
Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.
Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 33rd largest by enrollment, is one of 4 that started in 2010, is one of 23 in phase 3, and was the 37th registered.
252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.
Browse Dwarfism, Pituitary studies →3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 21–55
Baylor College of Medicine · Sites in United States
Ages 18–64
Changchun GeneScience Pharmaceutical Co., Ltd.
Ages 6 mo–17 yrs
By country, each count listing its studies:
Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 24 · Phase 4 19
First in 1997; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is close to the median of 60 across 169 interventional studies indexed under Dwarfism, Pituitary.
Median enrollment 66 across the 60 interventional studies. Of the 46 that completed or were terminated, 17 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under EMD Serono, one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.
13 studies in Dwarfism, Pituitary by Merck KGaA, Darmstadt, Germany: none open now, none under way, none of them phase 3. Of 13 finished, 7 (54%) have results posted.
Among the 13 studies in Dwarfism, Pituitary by Merck KGaA, Darmstadt, Germany, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2010, is one of 3 in phase 3, and was the 11th registered.
Merck KGaA, Darmstadt, Germany’s Dwarfism, Pituitary studies by the year they started, since 2003.
2 of the studies testing Human Growth Hormone in Dwarfism, Pituitary that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04867317Phase 3VA Office of Research and DevelopmentGrowth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD) | 2027-02-28 |
| NCT05355272Baylor College of MedicineGrowth Hormone Replacement in Veterans With GWI and AGHD (GWIT) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck KGaA, Darmstadt, Germany’s 13 in Dwarfism, Pituitary:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the immunogenicity of Saizen® solution for injection in adult subjects with documented Growth Hormone Deficiency (GHD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Saizen®
Single dose of Saizen® (recombinant human growth hormone, r-hGH) solution for injection will be administered subcutaneously for 26 weeks. Dosage regimen will be in accordance with marketed formulation of Saizen® (freeze-dried formulation), based on locally approved product labeling.
Also known as: r-hGH, Somatropin
Number of Participants Who Developed Positive Binding Antibodies (BAbs+) to Saizen®
Binding antibodies (BAbs) are all antibodies which are capable of binding to the investigational drug molecule (Saizen®), irrespective of their binding site.
Time frame: Baseline up to Week 26
Number of Participants Who Developed Positive Neutralizing Antibodies (NAbs+) to Saizen®
Neutralizing antibodies (NAbs) are defined as a subgroup of BAbs which bind to the active sites of the investigational drug molecule (Saizen®) and therefore neutralize its potency.
Time frame: Baseline up to Week 26
Insulin-like Growth Factor-I (IGF-1) Levels
Time frame: Baseline, Week 2, Week 4, Week 8, Week 13, Week 18, Week 26
Insulin-like Growth Factor-I Standard Deviation Score (IGF-1 SDS)
Insulin-like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) was provided by the central laboratory; its calculation is based on the actual value of IGF-1 minus mean reference value of IGF-1 divided by reference standard deviation of IGF-1.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 13, Week 18, Week 26
Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Levels
Time frame: Baseline, Week 2, Week 4, Week 8, Week 13, Week 18, Week 26
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Adverse events (AEs): Any untoward medical occurrence in the form of signs, clinically significant abnormalities in laboratory findings, diseases, symptoms, or worsening of complications. TEAEs: AEs occurring after the first administration of Saizen® solution for injection (on Day 1) up to the scheduled routine post treatment follow-up visit (4 weeks \[28 days\] after the final administration of Saizen® solution for injection).
Time frame: Day 1 up to 28 days after last dose of study treatment
| Milestone | Saizen® |
|---|---|
| Started | 59 |
| Completed | 19 |
| Not completed | 40 |
| Withdrew: Adverse event | 3 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Early termination of the trial | 36 |
Binding antibodies (BAbs) are all antibodies which are capable of binding to the investigational drug molecule (Saizen®), irrespective of their binding site.
| participants | Saizen® |
|---|---|
| Number of Participants Who Developed Positive Binding Antibodies (BAbs+) to Saizen® | 1 |
Neutralizing antibodies (NAbs) are defined as a subgroup of BAbs which bind to the active sites of the investigational drug molecule (Saizen®) and therefore neutralize its potency.
| participants | Saizen® |
|---|---|
| Number of Participants Who Developed Positive Neutralizing Antibodies (NAbs+) to Saizen® | 0 |
| nanomole per liter (nmol/L) | GH Treatment-Naive | GH Treatment-Experienced |
|---|---|---|
| Baseline (n = 49, 8) | 11.492 ± 6.694 | 20.225 ± 10.194 |
| Week 2 (n = 47, 8) | 18.923 ± 10.394 | 28.663 ± 9.001 |
| Week 4 (n = 49, 8) | 19.914 ± 11.532 | 24.500 ± 11.176 |
| Week 8 (n = 49, 8) | 21.155 ± 10.520 | 27.075 ± 6.815 |
| Week 13 (n = 46, 8) | 23.415 ± 8.020 | 26.413 ± 8.767 |
| Week 18 (n = 31, 4) | 24.948 ± 9.300 | 25.650 ± 8.502 |
| Week 26 (n = 48, 8) | 24.117 ± 11.085 | 27.438 ± 12.402 |
Insulin-like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) was provided by the central laboratory; its calculation is based on the actual value of IGF-1 minus mean reference value of IGF-1 divided by reference standard deviation of IGF-1.
| standard deviation score | GH Treatment-Naive | GH Treatment-Experienced |
|---|---|---|
| Baseline (n = 49, 8) | -2.914 ± 2.268 | -0.550 ± 2.274 |
| Week 2 (n = 47, 8) | -0.926 ± 2.300 | 0.951 ± 1.411 |
| Week 4 (n = 49, 8) | -0.867 ± 2.615 | 0.153 ± 1.762 |
| Week 8 (n = 49, 8) | -0.464 ± 2.274 | 0.834 ± 1.063 |
| Week 13 (n = 46, 8) | 0.212 ± 1.832 | 0.666 ± 1.225 |
| Week 18 (n = 31, 4) | 0.455 ± 1.816 | 1.043 ± 1.144 |
| Week 26 (n = 48, 8) | 0.167 ± 2.016 | 0.544 ± 1.894 |
| nmol/L | GH Treatment-Naive | GH Treatment-Experienced |
|---|---|---|
| Baseline (n = 51, 8) | 124.941 ± 31.899 | 133.375 ± 36.024 |
| Week 2 (n = 49, 8) | 137.408 ± 35.088 | 162.125 ± 35.203 |
| Week 4 (n = 49, 8) | 144.592 ± 32.632 | 147.750 ± 26.451 |
| Week 8 (n = 50, 8) | 147.460 ± 36.381 | 156.625 ± 36.190 |
| Week 13 (n = 47, 8) | 149.404 ± 28.272 | 151.875 ± 35.679 |
| Week 18 (n = 32, 4) | 148.813 ± 39.754 | 155.500 ± 36.235 |
| Week 26 (n = 49, 8) | 152.429 ± 35.649 | 147.500 ± 30.402 |
Adverse events (AEs): Any untoward medical occurrence in the form of signs, clinically significant abnormalities in laboratory findings, diseases, symptoms, or worsening of complications. TEAEs: AEs occurring after the first administration of Saizen® solution for injection (on Day 1) up to the scheduled routine post treatment follow-up visit (4 weeks \[28 days\] after the final administration of Saizen® solution for injection).
| participants | Saizen® |
|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 40 |
Collected over Day 1 up to 28 days after last dose of study treatment. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Saizen® | — | 3/59 (5.1%) | 13/59 (22%) |
| Event | Saizen® |
|---|---|
| AnxietyPsychiatric disorders | 1/59 |
| DepressionPsychiatric disorders | 1/59 |
| Hepatic enzyme increasedInvestigations | 1/59 |
| HyponatraemiaMetabolism and nutrition disorders | 1/59 |
| Event | Saizen® |
|---|---|
| Oedema peripheralGeneral disorders | 5/59 |
| NasopharyngitisInfections and infestations | 4/59 |
| HeadacheNervous system disorders | 3/59 |
| Insulin-like growth factor increasedInvestigations | 3/59 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/59 |
| Age Continuous(years) | Saizen® |
|---|---|
| Mean | 44.7 ± 10.3 |
| Sex: Female, Male(Participants) | Saizen® |
|---|---|
| Female | 30 |
| Male | 29 |
The record gives a start of Oct 2010, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone